Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 21, Issue 1, Pages 29-41Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2007.11.009
Keywords
acute myeloid leukemia; epigenetics; targeted therapy; ribonucleotide reductase; G3139 (oblimersen sodium, Genasense); core binding factor; KIT mutation; RAS mutation
Categories
Ask authors/readers for more resources
Today, treatment of patients with acute myeloid leukemia (AML) remains predominantly a one-fits-all approach with intensive cytarabine-based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, targeted therapy for each AML patient based on unique molecular features of disease remains a daunting goal, yet one that we can now begin to envision. Hypothesis-based study designs-from preclinical/laboratory experiments to phase I and subsequent efficacy trials-provide the foundation for advances in the diagnosis, risk stratification, and treatment of patients with AML. The following is an outline of several key areas of ongoing AML research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available